Weight-based strategy of dose administration in children using intravenous busulfan: Clinical and pharmacokinetic results

Pediatric Blood and Cancer

Volumn 58, Issue 1, 2012, Pages 90-97

  Michel, Gérard ^a   Valteau Couanet, Dominique ^b   Gentet, Jean Claude ^a   Esperou, Hélène ^c   Socié, Gérard ^c   Méchinaud, Françoise ^d   Doz, François ^e,f   Neven, Bénédicte ^g   Bertrand, Yves ^h   Galambrun, Claire ^a   Demeocq, François ⁱ   Yakouben, Karima ^j   Bordigoni, Pierre ^k   Frappaz, Didier ^h   Nguyen, Laurent ^l   Vassal, Gilles ^b  

^a TIMONE HOSPITAL   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔTEL DIEU   (France)

^e INSTITUT CURIE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HÔPITAL NECKER ENFANTS MALADES   (France)

^h IHOP   (France)

ⁱ HÔTEL DIEU   (France)

^j HÔPITAL ROBERT DEBRÉ   (France)

^k CHU NANCY BRABOIS   (France)

^l INSTITUT DE RECHERCHE PIERRE FABRE   (France)

more..

Author keywords

Children; Hematopoietic stem cell transplantation; Intravenous busulfan; Pediatrics; Pharmacokinetics

Indexed keywords

BENZODIAZEPINE; BUSULFAN; CYTARABINE; MELPHALAN;

ABDOMINAL PAIN; ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANOREXIA; ANXIETY DISORDER; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONFUSION; DELIRIUM; DIARRHEA; DRUG CLEARANCE; DRUG ERUPTION; DRUG SAFETY; DYSPNEA; EPISTAXIS; ESOPHAGITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HALLUCINATION; HEMATEMESIS; HEPATOMEGALY; HUMAN; HYPOXIA; INFANT; INFECTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PLEURA EFFUSION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHOOL CHILD; SEIZURE; SIDE EFFECT; STOMATITIS; UNSPECIFIED SIDE EFFECT; VEIN OCCLUSION; VOMITING;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; BODY WEIGHT; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; INFANT; INJECTIONS, INTRAVENOUS; MALE; PROGNOSIS; SURVIVAL RATE; TISSUE DISTRIBUTION; TRANSPLANTATION, HOMOLOGOUS;

EID: 81155133240     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22959     Document Type: Article

References (50)

1. Blaise D, Maraninchi D, Michallet M, et al. Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001;97:3669-3671.
2. Michel G, Gluckman E, Esperou-Bourdeau H, et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: Impact of conditioning regimen without total-body irradiation-a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994;12:1217-1222.
3. Fischer A, Griscelli C, Friedrich W, et al. Bone-marrow transplantation for immunodeficiencies and osteopetrosis: European survey, 1968-1985. Lancet 1986;2:1080-1084.
4. Santos GW. The development of busulfan/cyclophosphamide preparative regimens. Semin Oncol 1993;20:12-16.
5. Santos GW, Tutschka PJ, Brookmeyer R, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-1353.
6. Vassal G, Koscielny S, Challine D, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1995;37:247-253.
7. Grochow LB, Krivit W, Whitley CB, et al. Busulfan disposition in children. Blood 1990;75:1723-1727.
8. Hassan M, Ljungman P, Bolme P, et al. Busulfan bioavailability. Blood 1994;84:2144-2150.
9. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996;18:843-850.
10. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
11. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-3060.
12. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001;28:743-751.
13. Bolinger AM, Zangwill AB, Slattery JT, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000;25:925-930.
14. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:167-173.
15. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001;28:1013-1018.
16. Andersson BS, Kashyap A, Gian V, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant 2002;8:145-154.
17. Andersson BS, Thall PF, Madden T, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-485.
18. Thall PF, Champlin RE, Andersson BS. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects. Bone Marrow Transplant 2004;33:1191-1199.
19. Nguyen L. The impact of switching from oral IV busulfan of haematopoietic stem cell transplantation. EJHP Practice 2006;12:58-59.
20. Nguyen L, Leger F, Lennon S, et al. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: A population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191-198.
21. Leger F, Nguyen L, Puozzo C. Exposure equivalence between IV (0.8mg/kg) and oral (1mg/kg) busulfan in adult patients. Eur J Clin Pharmacol 2009;65:903-911.
22. Nguyen L, Fuller D, Lennon S, et al. I.V. busulfan in pediatrics: A novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004;33:979-987.
23. Vassal G, Michel G, Espérou H, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008;61:113-123.
24. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
25. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974;18:295-304.
26. EMA guideline ICH topic E6 guideline for good clinical practice. ICH Harmonised Tripartite Guideline, 1996.
27. Bouligand J, Le Maitre A, Valteau-Couanet D, et al. Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clin Pharmacol Ther 2007;82:402-409.
28. Ozkaynak MF, Weinberg K, Kohn D, et al. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: Incidence, risk factors, and clinical outcome. Bone Marrow Transplant 1991;7:467-474.
29. Kashyap A, Wingard J, Cagnoni P, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002;8:493-500.
30. Cesaro S, Pillon M, Talenti E, et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005;90:1396-1404.
31. Hasegawa S, Horibe K, Kawabe T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors. Bone Marrow Transplant 1998;22:1191-1197.
32. Cacchione A, LeMaitre A, Couanet DV, et al. Risk factors for hepatic veno-occlusive disease: A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. Bone Marrow Transplant 2008;42:449-454.
33. Copelan EA, Bechtel TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001;27:1121-1124.
34. Jones RJ, Lee KS, Beschorner WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
35. Anderson BJ, Meakin GH. Scaling for size: Some implications for paediatric anaesthesia dosing. Paediatr Anaesth 2002;12:205-219.
36. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303-332.
37. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 2008;47:231-243.
38. Gaziev J, Sodani P, Lucarelli G. Hematopoietic stem cell transplantation in thalassemia. Bone Marrow Transplant 2008;42:S41.
39. Bouligand J, Boland I, Valteau-Couanet D, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003;32:979-986.
40. Vassal G, Tranchand B, Valteau-Couanet D, et al. Pharmacodynamics of tandem high-dose melphalan with peripheral blood stem cell transplantation in children with neuroblastoma and medulloblastoma. Bone Marrow Transplant 2001;27:471-477.
41. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: Consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997;33:2126-2129.
42. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999;23:789-795.
43. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study. J Clin Oncol 2009;27:1007-1013.
44. Ladenstein R, Potschger U, Hartman O, et al. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: Lessons from more than 4000 procedures. Bone Marrow Transplant 2008;41:S118-S127.
45. Valteau-Couanet D, Benhamou E, Vassal G, et al. Consolidation with a busulfan-containing regimen followed by stem cell transplantation in infants with poor prognosis stage 4 neuroblastoma. Bone Marrow Transplant 2000;25:937-942.
46. Hoy SM, Lyseng-Williamson KA. Intravenous busulfan in the conditioning treatment of pediatric patients prior to hematopoietic stem cell transplantation. Paediatr Drugs 2007;9:271-278.
47. Gassas A, Ishaqi MK, Afzal S, et al. A comparison of the outcomes of children with acute myelogenous leukemia in either first or second complete remission (CR1 vs CR2) following allogeneic hematopoietic stem cell transplantation at a single transplant center. Bone Marrow Transplant 2008;41:941-945.
48. Dalle J, Caty L, Peffault R. Impact of conditioning regimen in allogeneic hematopoietic stem cell transplantation for children with acute myeloid leukemia in first complete remission: Total-body irradiation and cyclophosphamide versus busulfan and cyclophosphamide-A report from The Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Blood 2007;110:617.
49. Sandler ES, Hagg R, Coppes MJ, et al. Hematopoietic stem cell transplantation (HSCT) with a conditioning regimen of busulfan, cyclophosphamide, and etoposide for children with acute myelogenous leukemia (AML): A phase I study of the Pediatric Blood and Marrow Transplant Consortium. Med Pediatr Oncol 2000;35:403-409.
50. Gaziev J, Nguyen L, Puozzo C, et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010;115:4597-4604.